Welcome!

News Feed Item

MediPoint: Sports Medicine - US Analysis and Market Forecasts

NEW YORK, April 22, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Sports Medicine - US Analysis and Market Forecasts
http://www.reportlinker.com/p02081704/MediPoint-Sports-Medicine---US-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

MediPoint: Sports Medicine - US Analysis and Market Forecasts

Summary

This report focuses on the sports medicine market, which includes implants and arthroscopic capital equipment. The orthopedic sports medicine market has been estimated in this report and covers the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China and India. The report provides unmet needs, future adoption and compound annual growth rates (CAGR). GlobalData's analysis shows that while the orthopedics implant market is mature, sports medicine is an area with the potential for significant international growth. With the market, the US remains to be the largest market with the EU to follow and growing. The APAC region while markedly smaller has a large potential patient population.The top six to seven market leaders continue to dominate the market through technological innovation and investment in establishing strong distribution networks. The major opportunity lies within technological advancement and the clinical trials to prove effectiveness of new techniques.

The US sports medicine market is a strong and growing market, with prevalence of sports-related injury rising most rapidly among the young and old. The biggest player in sports medicine in the US remains Arthrex, leading with a 21% market share. This company has the strongest brand identity and offers a wide selection of products, which makes it competitive and able to maintain its market share.

Scope

- An overview of sports medicine, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized the US sports medicine market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for sports medicine.
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the sports medicine sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

- Understand the trends shaping and driving the US sports medicine market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US sports medicine market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in the US sports medicine market landscape? Identify, understand and capitalize.
1 Table of Contents

2 Introduction 20
2.1 Catalyst 21
2.2 Related Reports 22
2.3 Upcoming Related Reports 22
3 Clinical Outcomes 23
3.1 Conservative Treatments 23
3.1.1 Immobilization and Bracing 24
3.1.2 Physical Therapy 24
3.1.3 Muscle Stimulation 25
3.2 Drug Therapy 25
3.2.1 Nutritional Supplements 26
3.2.2 Analgesics and NSAIDs 26
3.2.3 Corticosteroids 26
3.2.4 Viscosupplementation 26
3.3 Soft Tissue Repair 27
3.4 Arthroscopy 29
3.5 Plates and Screws 30
3.6 Joint Replacement 30
4 Industry Overview 32
4.1 Overview 32
4.2 Procedure Trends 33
4.2.1 US 33
4.3 Market Access 35
4.3.1 US 35
4.4 Disputes and Settlements 40
4.4.1 Smith & Nephew Granted an Injunction Against Arthrex 40
4.4.2 KFx Medical and Smith & Nephew Enter Into Licensing Agreement 40
4.4.3 KFx Medical Wins Patent Infringement Lawsuit Against Arthrex 40
4.4.4 ArthroCare and Smith & Nephew Settle Legal Disputes 40
4.5 Mergers, Acquisitions, Partnerships, and Other Deals 40
4.5.1 Stryker Acquires Pivot Medical 40
4.5.2 Smith & Nephew Announces Acquisition of ArthroCare 41
4.5.3 Smith & Nephew Acquires Plato Grup Assets 41
4.5.4 Smith & Nephew Announces Acquisition of Its Brazil Distribution Business 41
4.5.5 Kensey Nash Acquires Minority Stake in Orteq Sports Medicine 41
4.5.6 Tornier Acquires C2M Medical 42
4.5.7 Tornier Signs Licensing Agreement with T.A.G. Medical Products Corporation 42
4.5.8 Biomet Acquires Cartilix 42
4.5.9 Biomet Sports Medicine Enters Into Deal With Marc Tec 42
4.6 Economic Impact 42
4.6.1 Developed Countries 42
4.6.2 Emerging Markets 45
5 Unmet Needs 46
5.1 Long-Term Clinical Data 46
5.1.1 Hip Arthroscopic Implants Clinical Data 46
5.1.2 Rotator Cuff Injury Clinical Data 46
5.2 Cartilage and Meniscal Repair Product Development 47
5.2.1 Knee Meniscus Treatment 47
5.2.2 Hip Cartilage Product Development 49
5.3 Biologics for Faster Healing 50
5.4 Standardization and Improvement of Instruments 51
5.4.1 Hip and Shoulder Instrumentation 51
5.4.2 Screwdriver Standardization 51
5.5 Fellowship Training Programs 52
5.6 Advanced Materials Research 53
5.7 Bioabsorbable Technology Development 54
5.8 Centralization 56
5.9 Need for Cost-Containment 56
5.10 Suture Anchor Product Development 57
6 Market Opportunity Analysis 59
6.1 Adding More Training Programs 59
6.2 Product Line Extensions 59
6.3 Lack of Pricing Pressure in Sports Medicine 60
6.4 Mergers and Acquisitions 61
6.5 Seasonality of Sports Medicine 62
6.6 Emerging Markets 62
6.7 Minimally-Invasive Surgical Preference 63
7 Market Drivers, Barriers and Substitutes 64
7.1 Driver: Rising Prevalence 64
7.1.1 Sports-Related Injuries 64
7.1.2 Aging 64
7.1.3 Trauma 65
7.2 Driver: Hip Arthroscopy 66
7.2.1 Femoroacetabular Impingement Growth 67
7.2.2 Hip Arthroscopy Fellowship Training Programs 68
7.3 Driver: Knee and Shoulder Arthroscopy 68
7.4 Driver: Revision Surgery 69
7.5 Driver: Patient Demand and Awareness 70
7.6 Driver: Orthobiologics Development 71
7.6.1 Bone Grafts 71
7.6.2 Platelet-Rich Plasma 72
7.7 Driver: Rising Competition and Innovation Through Small Players 72
7.8 Driver: Materials Development 72
7.8.1 Composite Materials and Biopolymers 73
7.8.2 Bioabsorbables 73
7.8.3 Metallic Alloys in Orthopedics 74
7.9 Barrier: Arthroscopy's Questionable Outcomes 75
7.9.1 Hip Arthroscopy 75
7.9.2 Knee Arthroscopy 76
7.10 Barrier: Steep Learning Curve 77
7.11 Barrier: Reimbursement 77
7.12 Barrier: Burden of Rising Regulation 79
7.13 Barrier: Proving Efficacy 80
7.14 Barrier: Medical Device Excise Tax 81
7.15 Substitute: Open Surgery Versus Minimally-Invasive Arthroscopy 81
7.16 Substitute: Conservative Treatment Options 82
8 Competitive Assessment 83
8.1 Overview 83
8.2 Marketed Products in Sports Medicine 83
8.2.1 Arthrex 83
8.2.2 ArthroCare Corporation 90
8.2.3 Biomet 94
8.2.4 ConMed Corporation 98
8.2.5 DePuy Mitek 103
8.2.6 Smith & Nephew 106
8.2.7 Stryker 109
8.2.8 Tornier 111
9 Pipeline Assessment 113
9.1 Overview 113
9.2 Product Profiles 113
9.2.1 Bioretec Drug-Releasing Screws 113
9.2.2 Nanova Bioabsorbable Bone Screws 113
9.2.3 MinInvasive Arthroscopic Suture Passer 113
9.2.4 SpineSmith Pipeline 114
9.2.5 DePuy Mitek FMS VUE 114
9.2.6 Pivot Medical Hip Arthroscopy System 114
9.2.7 University of Florida Shoulder Labral Anchor Delivery System 114
9.2.8 University of California at San Diego Cartilage Regeneration Device 114
10 Clinical Trials to Watch 115
10.1 Overview 115
10.2 Can Shoulder Arthroscopy Work (CSAW) Study 115
10.3 Arthroscopy in the Treatment of Degenerative Medial Meniscus Tear 115
10.4 Knee Arthroscopy Cohort Southern Denmark 116
10.5 Hip Arthroscopy Versus Conservative Management of Femoroacetabular Impingement 116
10.6 Femoroacetabular Impingement Randomized Controlled Trial 117
10.7 Multicenter ACL Revision Study (MARS) 117
10.8 Arthroscopic Versus Open Stabilization for Traumatic Shoulder Instability 118
10.9 Microfracture in the Knee Study 118
10.10 Single- Versus Double-Row Suture Anchor Repair in Medium to Large Rotator Cuff Tears 119
10.11 Early Surgery Versus Conservative Therapy for Meniscal Injuries in Older Patients (ESCAPE) 119
10.12 Arthroscopic Rotator Cuff Repair of Full Thickness Tears With and Without Arthroscopic Acromioplasty 120
10.13 Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma 121
10.14 Tibial Tunnel Widening in ACL Reconstruction-Comparing Two Bioscrews 121
11 Current and Future Players 122
11.1 Trends in Corporate Strategy 122
11.2 Company Profiles 123
11.2.1 Arthrex 123
11.2.2 ArthroCare Corporation 125
11.2.3 Biomet 127
11.2.4 ConMed Corporation 130
11.2.5 DePuy Companies 132
11.2.6 Smith & Nephew 134
11.2.7 Stryker 136
11.2.8 Tornier 138
11.2.9 Wright Medical Group 141
11.2.10 Other Key Players in Sports Medicine 144
12 Market Outlook 149
12.1 Company Market Share 149
12.1.1 Overview 149
12.1.2 US 149
12.2 US Market Outlook 150
13 Appendix 153
13.1 Bibliography 153
13.2 Abbreviations 162
13.3 Research Methodology 166
13.3.1 Overview 166
13.3.2 Coverage 166
13.3.3 Secondary Research 166
13.4 Physicians and Specialists Included in this Study 167
13.4.1 Dr. Henry D.E. Atkinson 167
13.4.2 Dr. Joshua Alpert 167
13.4.3 Dr. Andrea Ferretti 167
13.4.4 Dr. Alejandro Gonzalez Della Valle 168
13.4.5 Dr. Andreas Imhoff 168
13.4.6 Dr. Marcello Zaia Oliveira 168
13.4.7 Dr. Vidhya Ravi 168
13.4.8 Dr. Elvire Servien 168
13.4.9 Dr. Yotaro Yamakado 168
13.5 Primary Research 169
13.5.1 Primary Research - Key Opinion Leader Interviews 169
13.5.2 Primary Research - Physician and Industry Interviews 169
13.5.3 Expert Panel Validation 170
13.6 Forecasting Methodology 170
13.7 About the Authors 172
13.7.1 Analysts 172
13.7.2 Global Head of Healthcare 173
13.8 About MediPoint 174
13.9 About GlobalData 174
13.10 Disclaimer 174

1.1 List of Tables

Table 1: Most Common Soft Tissue Injuries to the Extremities in Sports Medicine 28
Table 2: Growth Rates for Arthroscopy by Joint in the US, 2013-2020 34
Table 3: Medicare ICD-9 Diagnosis Codes for Common Sports Medicine Injuries, 2013 38
Table 4: Medicare National Adjusted Reimbursement Rates for Common Sports Medicine Injuries for Hospital Outpatient Treatment, 2013 39
Table 5: Medicare DRG Payments to Hospitals for Common Sports Medicine Injuries, 2013 39
Table 6: Direct, Indirect, and Intangible Costs of Orthopedics 44
Table 7: Potential Market for Meniscus Treatment Types 48
Table 8: Metal Implant CharacteristicsThat Can Be Improved 74
Table 9: Arthrex Shoulder Implants 85
Table 10: Arthrex, Shoulder Instrumentation 86
Table 11: Arthrex, Knee Sutures and Suture Anchors 86
Table 12: Arthrex, Knee Graft Fixation Devices and Meniscal Products 87
Table 13: Arthrex, Hip Implants and Instruments 88
Table 14: Arthrex, Arthroscopy Procedure Capital Equipment 89
Table 15: Arthrex, Implants SWOT Analysis 89
Table 16: Arthrex, Instrumentation SWOT Analysis 90
Table 17: Arthrocare, Suture Implants 91
Table 18: ArthroCare, Suture Management Products 92
Table 19: ArthroCare, Cruciate Ligament Graft Fixation Products 93
Table 20: ArthroCare, Capital Equipment and Instruments 93
Table 21: ArthroCare, Implants SWOT Analysis 94
Table 22: Arthrocare, Instruments and Capital Equipment SWOT Analysis 94
Table 23: Biomet, Shoulder Arthroscopy Products 95
Table 24: Biomet, Knee Arthroscopy Products 96
Table 25: Biomet's Other Joints Arthroscopy Products 97
Table 26: Biomet, Capital Equipment Sports Medicine Products 97
Table 27: Biomet Implants SWOT Analysis 98
Table 28: Biomet, Capital Equipment SWOT Analysis 98
Table 29: ConMed, Shoulder Arthroscopy Products 99
Table 30: ConMed, Knee Arthroscopy Products 100
Table 31: ConMed, Small Joint and Hip Arthroscopy Products 101
Table 32: ConMed, Instruments and Capital Equipment 102
Table 33: ConMed, Implants SWOT Analysis 102
Table 34: ConMed, Capital Equipment SWOT Analysis 103
Table 35: DePuy Mitek, Fixation Devices 104
Table 36: DePuy, Mitek Instruments 105
Table 37: DePuy Mitek, Capital Equipment 105
Table 38: DePuy Mitek Implants, SWOT Analysis 106
Table 39: DePuy Mitek, Capital Equipment SWOT Analysis 106
Table 40: Smith & Nephew, Fixation Devices 107
Table 41: Smith & Nephew, Instruments and Capital Equipment 108
Table 42: Smith & Nephew Implants, SWOT Analysis 108
Table 43: Smith & Nephew, Capital Equipment SWOT Analysis 109
Table 44: Stryker, Fixation Devices 109
Table 45: Stryker, Instrumentation 110
Table 46: Stryker, Capital Equipment 110
Table 47: Stryker, Fixation Devices SWOT Analysis 111
Table 48: Stryker, Instrumentation and Capital Equipment SWOT Analysis 111
Table 49: Tornier Sports Medicine Products 112
Table 50: Tornier, Product Family SWOT Analysis 112
Table 51: Can Shoulder Arthroscopy Work (CSAW) 115
Table 52: Arthroscopy in the Treatment of Degenerative Medial Meniscus Tear 116
Table 53: Knee Arthroscopy Cohort Southern Denmark 116
Table 54: Hip Arthroscopy Versus Conservative Management of Femoroacetabular Impingement 117
Table 55: Femoroacetabular Impingement Randomized Controlled Trial 117
Table 56: Multicenter ACL Revision Study (MARS) 118
Table 57: Arthroscopic Versus Open Stabilization for Traumatic Shoulder Instability 118
Table 58: Results at 10 to 14 Years After Microfracture in the Knee 119
Table 59: Single Versus Double Row Suture Anchor Repair in Medium to Large Rotator Cuff Tears 119
Table 60: Early Surgery Versus Conservative Therapy for Meniscal Injuries in Older Patients (ESCAPE) 120
Table 61: Arthroscopic Rotator Cuff Repair of Full Thickness Tears With and Without Arthroscopic Acromioplasty 120
Table 62: Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma in Large to Massive Tears 121
Table 63: Tibial Tunnel Widening in Anterior Cruciate Ligament Reconstruction Comparing Two Bioscrews 121
Table 64: Company Profile - Arthrex 124
Table 65: SWOT Analysis - Arthrex 125
Table 66: Company Profile - ArthroCare Corporation 126
Table 67: SWOT Analysis - ArthroCare Corporation 127
Table 68: Company Profile - Biomet 128
Table 69: SWOT Analysis - Biomet 129
Table 70: Company Profile - ConMed Corporation 131
Table 71: SWOT Analysis - ConMed Corporation 132
Table 72: Company Profile - DePuy Companies 133
Table 73: SWOT Analysis - DePuy Companies 134
Table 74: Company Profile - Smith & Nephew 135
Table 75: SWOT Analysis - Smith & Nephew 136
Table 76: Company Profile - Stryker 137
Table 77: SWOT Analysis - Stryker 138
Table 78: Company Profile - Tornier 139
Table 79: SWOT Analysis - Tornier 140
Table 80: Company Profile - Wright Medical Group 142
Table 81: SWOT Analysis - Wright Medical Group 143
Table 82: Other Sports Medicine Companies in the US Market 144
Table 83: Other Sports Medicine Companies in the EU Market 145
Table 84: Other Sports Medicine Companies in the APAC Market 147
Table 85: US Sports Medicine Sales Forecast ($m), 2011-2020 152
Table 86: Primary Research Interviews Completed in Sports Medicine 170

1.2 List of Figures

Figure 1: Global Arthroscopic Procedure Volumes by Joint, 2011-2020 32
Figure 2: US Arthroscopic Procedure Volumes, 2011-2020 33
Figure 3: US Arthroscopic Procedure Volumes by Joint, 2011-2020 34
Figure 4: Sources of Orthopedic Trauma (%) (n=103) 66
Figure 5: US Market Share for Arthroscopy, 2012 150
Figure 6: US Sports Medicine Sales Forecast ($m), 2011-2020 152

To order this report: MediPoint: Sports Medicine - US Analysis and Market Forecasts
http://www.reportlinker.com/p02081704/MediPoint-Sports-Medicine---US-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Rapid innovation, changing business landscapes, and new IT demands force businesses to make changes quickly. In the eyes of many, containers are at the brink of becoming a pervasive technology in enterprise IT to accelerate application delivery. In this presentation, attendees learned about the: The transformation of IT to a DevOps, microservices, and container-based architecture What are containers and how DevOps practices can operate in a container-based environment A demonstration of how ...
Cloud Expo, Inc. has announced today that Andi Mann returns to 'DevOps at Cloud Expo 2017' as Conference Chair The @DevOpsSummit at Cloud Expo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great t...
"At ROHA we develop an app called Catcha. It was developed after we spent a year meeting with, talking to, interacting with senior citizens watching them use their smartphones and talking to them about how they use their smartphones so we could get to know their smartphone behavior," explained Dave Woods, Chief Innovation Officer at ROHA, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
SYS-CON Events has announced today that Roger Strukhoff has been named conference chair of Cloud Expo and @ThingsExpo 2017 New York. The 20th Cloud Expo and 7th @ThingsExpo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "The Internet of Things brings trillions of dollars of opportunity to developers and enterprise IT, no matter how you measure it," stated Roger Strukhoff. "More importantly, it leverages the power of devices and the Internet to enable us all to im...
Effectively SMBs and government programs must address compounded regulatory compliance requirements. The most recent are Controlled Unclassified Information and the EU's GDPR have Board Level implications. Managing sensitive data protection will likely result in acquisition criteria, demonstration requests and new requirements. Developers, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by incorporating changes. In...
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor – all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
"Qosmos has launched L7Viewer, a network traffic analysis tool, so it analyzes all the traffic between the virtual machine and the data center and the virtual machine and the external world," stated Sebastien Synold, Product Line Manager at Qosmos, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
The WebRTC Summit New York, to be held June 6-8, 2017, at the Javits Center in New York City, NY, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 20th International Cloud Expo and @ThingsExpo. WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web co...
Successful digital transformation requires new organizational competencies and capabilities. Research tells us that the biggest impediment to successful transformation is human; consequently, the biggest enabler is a properly skilled and empowered workforce. In the digital age, new individual and collective competencies are required. In his session at 19th Cloud Expo, Bob Newhouse, CEO and founder of Agilitiv, drew together recent research and lessons learned from emerging and established compa...